Study guide

6.2 Federal & Oklahoma Controlled Dangerous Substance Schedules

Oklahoma MPJE Pharmacy Jurisprudence Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 Oklahoma MPJE Format, Blueprint & Passing Standards 1.2 Navigating Oklahoma & Federal Pharmacy Law Hierarchy

2 Chapter 2: State Board Governance & Administrative Framework

2.1 Oklahoma State Board of Pharmacy Structure & Powers 2.2 Disciplinary Procedures, Sanctions & Hearings 2.3 Impaired Pharmacist Recovery Program & Duty to Report

3 Chapter 3: Pharmacist Licensure & Continuing Education

3.1 Pharmacist Licensure Qualifications & Examination Rules 3.2 Reciprocity & Foreign Pharmacy Graduates 3.3 Annual License Renewal & Continuing Education Mandates 3.4 Inactive Status, Late Renewal & License Reinstatement

4 Chapter 4: Pharmacy Interns, Preceptors & Supportive Personnel

4.1 Pharmacy Intern Qualifications & Preceptor Standards 4.2 Experiential Intern Hours, Credit & Board Reporting 4.3 Pharmacy Technician Permitting & Training Requirements 4.4 Pharmacist-to-Technician Ratios & Scope of Supportive Duties

5 Chapter 5: Prescription Validity & Prescriber Authority

5.1 Legal Requirements of a Valid Prescription 5.2 Prescriptive Authority & Scopes of Practice in Oklahoma 5.3 The Pharmacist's Corresponding Responsibility & Red Flags 5.4 Out-of-State, Military & Foreign Prescriptions

6 Chapter 6: Electronic Prescribing & Controlled Substance Schedules

6.1 Oklahoma Electronic Prescribing Mandate (EPCS) 6.2 Federal & Oklahoma Controlled Dangerous Substance Schedules 6.3 Scheduled Listed Chemical Products (SLCP) & Pseudoephedrine Sales 6.4 Schedule V Non-Prescription (Exempt) Controlled Substances

7 Chapter 7: Controlled Substance Dispensing & Opioid Limits

7.1 Schedule II Prescribing & Dispensing Regulations 7.2 Emergency Schedule II Oral Authorizations 7.3 Partial Filling of Schedule II Prescriptions (CARA & Title 63) 7.4 Oklahoma Opioid Prescribing Limits for Acute Pain

8 Chapter 8: Patient Counseling, Safety & Clinical Pharmacy Services

8.1 Patient Counseling Mandates & OBRA '90 8.2 Prospective Drug Utilization Review (DUR) Requirements 8.3 Pharmacist Immunization Administration Authority 8.4 Naloxone Standing Orders, Overdose Prevention & Clinical Protocols 8.5 Patient Confidentiality, HIPAA Privacy & Health-Record Protection

9 Chapter 9: Dispensing Standards, Generic Substitution & Labeling

9.1 Oklahoma Generic Drug Substitution Laws (Orange Book) 9.2 Biosimilar & Interchangeable Biological Products (Purple Book) 9.3 Prescription Refill Limits & Emergency Maintenance Fills 9.4 Prescription Labeling, Poison Prevention Packaging (PPPA) & USP Standards 9.5 Expired, Adulterated, Misbranded & Recalled Drug Products 9.6 Nonprescription Drug Labeling, Packaging & Repackaging 9.7 Returning & Reusing Drugs: Return-to-Stock, Donation & Disposal

10 Chapter 10: Prescription Transfers, Delivery & Monitoring Systems

10.1 Prescription Transfer Rules (Controlled vs. Non-Controlled) 10.2 Oklahoma Prescription Monitoring Program (OK PMP / PMP AWARxE) 10.3 Central Fill, Mail-Order & Prescription Delivery Regulations 10.4 Automated Dispensing Systems (ADS) & Remote Pharmacy Services

11 Chapter 11: Pharmacy Permits, Facilities & Operational Standards

11.1 Oklahoma Pharmacy Licenses & Permits 11.2 Pharmacist-in-Charge (PIC) Governance & Requirements 11.3 Physical Plant, Security & Sanitation Standards 11.4 Pharmacy Permanent Closing & Change of Ownership

12 Chapter 12: Controlled Substance Management, Ordering & Security

12.1 Pharmacy DEA & OBNDD Registration Requirements 12.2 Controlled Substance Ordering (DEA Form 222 & CSOS) 12.3 Controlled Substance Physical Inventory Requirements 12.4 Theft, Significant Loss & CDS Destruction (DEA Form 106 & Form 41)

13 Chapter 13: Compounding Standards & Institutional Practice

13.1 Non-Sterile (USP <795>) & Sterile (USP <797>) Compounding 13.2 Hazardous Drug Handling (USP <800>) 13.3 Hospital & Institutional Pharmacy Operations (Hospital Pharmacies & Drug Rooms) 13.4 Nuclear, Charitable & Specialty Pharmacy Standards

6.2 Federal & Oklahoma Controlled Dangerous Substance Schedules

Key Takeaways Explain This Topic AI

Controlled Dangerous Substances (CDS) are categorized into Schedules I through V based on accepted medical use, relative abuse potential, and physical/psychological dependence liability under the Federal CSA and Title 63 O.S.

All hydrocodone combination products (e.g., Norco, Vicodin, Lortab) are classified as Schedule II CDS at both federal and Oklahoma state levels.

Tramadol (Ultram) and carisoprodol (Soma) are classified as Schedule IV CDS, buprenorphine products (Suboxone, Subutex) are Schedule III CDS, and pregabalin (Lyrica) is Schedule V CDS.

Dronabinol formulations have distinct schedule classifications: FDA-approved oral solution containing alcohol (Syndros) is Schedule II, whereas oral capsules formulated in sesame oil (Marinol) are Schedule III.

Last updated: November 2026

6.2 Federal & Oklahoma Controlled Dangerous Substance Schedules

Core Legal Framework: Both the Federal Controlled Substances Act (21 U.S.C. § 812; 21 CFR Part 1308) and the Oklahoma Uniform Controlled Dangerous Substances Act (Title 63 O.S. § 2-201 through § 2-212) classify drugs into five distinct schedules (Schedules I through V). Scheduling determinations are based on three fundamental statutory criteria: (1) currently accepted medical use in the United States, (2) relative potential for abuse, and (3) severity of physical or psychological dependence liability.

1. Statutory Criteria for the Five CDS Schedules +------------------------------------------------------------------------------------------------+

  • | CONTROLLED DANGEROUS SUBSTANCE (CDS) SCHEDULE CRITERIA |
  • +----------+--------------------+-------------------------+--------------------------------------+
  • | Schedule | Abuse Potential | Accepted U.S. Med Use | Dependence Liability |
  • +----------+--------------------+-------------------------+--------------------------------------+
  • | **C-I** | High | None | Lack of accepted safety under care |
  • | **C-II** | High | Yes (with restrictions) | Severe physical / psychological |
  • | **C-III**| Moderate / Low | Yes | Moderate physical / High psych |
  • | **C-IV** | Low (rel. to C-III)| Yes | Limited physical / psychological |
  • | **C-V** | Low (rel. to C-IV) | Yes | Very limited physical / psychological|
  • +----------+--------------------+-------------------------+--------------------------------------+
  • 2. Detailed Breakdown of Schedules & Representative Agents
  • Schedule I (C-I)

Statutory Profile: High abuse potential; no currently accepted medical use in treatment in the United States; lacks accepted safety data even under close medical supervision.

Key Representative Agents:

Illicit Narcotics: Heroin, illicit Fentanyl analogues (e.g., acetylfentanyl, carfentanil).

Hallucinogens: Lysergic acid diethylamide (LSD), Mescaline, Peyote, Psilocybin, 3,4-Methylenedioxymethamphetamine (MDMA / Ecstasy).

Depressants: Methaqualone (Quaalude), Gamma-Hydroxybutyric Acid (GHB) illicit preparations.

Synthetic Cannabinoids: Synthetic cannabinoid receptor agonists ("Spice", "K2"), Methcathinone, Bath salts (synthetic cathinones).

Jurisprudential Note on Marijuana: Under federal law, marijuana in an FDA-approved drug product and marijuana subject to a state medical marijuana license have been Schedule III since April 28, 2026 (91 FR 22714); all other marijuana remains Schedule I. In Oklahoma, the passage of State Question 788 created a licensed medical marijuana system under Title 63 O.S. (Oklahoma Medical Marijuana Authority - OMMA); however, medical marijuana is not dispensed from standard licensed pharmacies and cannot be prescribed via federal DEA registrations.

Schedule II (C-II)

Statutory Profile: High abuse potential; accepted medical use in the United States (often with severe restrictions); abuse may lead to severe psychological or physical dependence.

Key Representative Agents:

Opioid Agonists: Morphine, Oxycodone (OxyContin, Roxicodone, Percocet), Hydromorphone (Dilaudid), Oxymorphone (Opana), Fentanyl (Duragesic, Actiq, Fentora), Methadone (Dolophine), Meperidine (Demerol), Codeine (single ingredient), Hydrocodone combination products (Norco, Vicodin, Lortab, Lorcet), Tapentadol (Nucynta), Sufentanil.

CNS Stimulants: Amphetamine mixed salts (Adderall), Dextroamphetamine (Dexedrine), Methylphenidate (Ritalin, Concerta), Dexmethylphenidate (Focalin), Lisdexamfetamine (Vyvanse), Methamphetamine (Desoxyn), Cocaine (topical medical solution).

Barbiturates & Depressants: Pentobarbital (Nembutal), Secobarbital (Seconal), Amobarbital (Amytal).

Specific Formulation: Dronabinol oral solution (Syndros) — formulated with 50% alcohol; classified in Schedule II due to rapid absorption and formulation abuse potential.

Schedule III (C-III)

Statutory Profile: Abuse potential less than substances in Schedules I and II; accepted medical use; abuse may lead to moderate or low physical dependence or high psychological dependence.

Key Representative Agents:

Buprenorphine Products: Buprenorphine single-ingredient (Subutex) and Buprenorphine/Naloxone combinations (Suboxone, Zubsolv) used in opioid use disorder treatment and pain management (Belbuca, Butrans).

Anabolic Steroids: Testosterone (AndroGel, Depo-Testosterone), Nandrolone, Oxandrolone, Stanozolol, Methandrostenolone.

Barbiturate Combinations: Butalbital-containing products with aspirin (Fiorinal). (Note: Fioricet containing butalbital/APAP/caffeine is federally exempt from scheduling due to its ratio, but tracked closely in Oklahoma practice). Also includes suppository forms of Amobarbital, Secobarbital, or Pentobarbital.

Dissociative Anesthetics: Ketamine (Ketalar).

Specific Formulation: Dronabinol capsules in sesame oil (Marinol) — formulated in soft gelatin capsules; classified in Schedule III.

Codeine Combination Thresholds: Products containing not more than 90 mg of codeine per dosage unit combined with an equal or greater quantity of an isoquinoline alkaloid or with one or more active non-narcotic therapeutic ingredients (e.g., Acetaminophen with Codeine #3 [30 mg codeine] and #4 [60 mg codeine]).

Schedule IV (C-IV)

Statutory Profile: Low potential for abuse relative to Schedule III substances; accepted medical use; abuse may lead to limited physical or psychological dependence.

Key Representative Agents:

Benzodiazepines: Alprazolam (Xanax), Diazepam (Valium), Lorazepam (Ativan), Clonazepam (Klonopin), Temazepam (Restoril), Triazolam (Halcion), Midazolam (Versed), Chlordiazepoxide (Librium), Clobazam (Onfi).

Non-Benzodiazepine Sedatives ("Z-Drugs"): Zolpidem (Ambien), Zaleplon (Sonata), Eszopiclone (Lunesta).

Skeletal Muscle Relaxants: Carisoprodol (Soma) — federally and state-classified as Schedule IV.

Synthetic Opioid Analgesics: Tramadol (Ultram, Ultracet) — federally and state-classified as Schedule IV.

Orexin Receptor Antagonists: Suvorexant (Belsomra), Lemborexant (Dayvigo), Daridorexant (Quviviq).

Wakefulness Promoters: Modafinil (Provigil), Armodafinil (Nuvigil).

Long-Acting Barbiturates: Phenobarbital.

Weight Loss Agents: Phentermine (Adipex-P), Diethylpropion, Lorcaserin (Belviq - withdrawn).

Gastrointestinal Antidiarrheal: Difenoxin 1 mg / Atropine 25 mcg (Motofen).

Schedule V (C-V)

Statutory Profile: Low potential for abuse relative to Schedule IV substances; accepted medical use; limited physical or psychological dependence liability relative to higher schedules.

Key Representative Agents:

Anticonvulsants & Neuropathic Agents: Pregabalin (Lyrica), Lacosamide (Vimpat), Brivaracetam (Briviact), Cenobamate (Xcopri).

Antidiarrheals: Diphenoxylate 2.5 mg combined with not less than 25 mcg of Atropine Sulfate per dosage unit (Lomotil).

Antitussive Formulations: Liquid preparations containing not more than 200 mg of codeine per 100 mL (or 100 g) with one or more non-narcotic active medicinal ingredients (e.g., Promethazine with Codeine, Guaifenesin with Codeine / Cheratussin AC).

3. High-Yield Scheduling Thresholds & Calculation Rules

Oklahoma MPJE questions frequently test the precise concentration and dosage limits dividing narcotic schedules:

A. Codeine Combination Limits

Schedule II: Pure codeine single-ingredient (any strength) or combinations exceeding 90 mg per dosage unit / 1.8 g per 100 mL.

Schedule III: Combinations containing ≤ 90 mg of codeine per dosage unit (e.g., Tylenol with Codeine #3 has 30 mg codeine, Tylenol with Codeine #4 has 60 mg codeine) OR ≤ 1.8 g of codeine per 100 mL (18 mg/mL), provided it is combined with one or more active non-narcotic ingredients in recognized therapeutic amounts.

Schedule V: Liquid combinations containing ≤ 200 mg of codeine per 100 mL (2 mg/mL or 10 mg/5 mL) combined with one or more non-narcotic active ingredients (e.g., Guaifenesin with Codeine syrup).

B. Dronabinol Formulation Rules

Marinol (Dronabinol Capsules): Synthetic delta-9-tetrahydrocannabinol dissolved in sesame oil and encapsulated in soft gelatin is Schedule III .

Syndros (Dronabinol Oral Solution): Liquid formulation dissolved in 50% alcohol solution is Schedule II due to higher abuse and extraction potential.

C. Rescheduled & Frequently Tested Controlled Substances

Medication Current Schedule Historical Context & Exam Nuance

Hydrocodone Combinations (Norco, Lortab) Schedule II Rescheduled federally and in Oklahoma from C-III to C-II in October 2014. No refills permitted.

Tramadol (Ultram) Schedule IV Placed into Schedule IV federally in August 2014. Max 5 refills / 6-month expiration.

Carisoprodol (Soma) Schedule IV Placed into Schedule IV federally in January 2012. Meprobamate active metabolite.

Buprenorphine (Suboxone, Subutex) Schedule III Partial mu-agonist; C-III prescribing rules apply.

Pregabalin (Lyrica) Schedule V Schedule V anticonvulsant; requires prescription in Oklahoma.

Epidiolex (Cannabidiol Oral Solution) Non-Controlled (Rx) Descheduled completely by DEA in April 2020 following FDA approval of pure CBD.

Loading diagram... Controlled Dangerous Substance (CDS) Scheduling Hierarchy & Key Drugs